These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. Dagenais GR; Jung H; Lonn E; Bogaty PM; Dehghan M; Held C; Avezum A; Jansky P; Keltai M; Leiter LA; Lopez-Jaramillo P; Toff WD; Bosch J; Yusuf S J Am Heart Assoc; 2018 Jul; 7(15):. PubMed ID: 30033433 [TBL] [Abstract][Full Text] [Related]
8. Blood pressure lowering does not reduce risk of cardiovascular events in patients at intermediate risk. Torjesen I BMJ; 2016 Apr; 353():i1899. PubMed ID: 27044631 [No Abstract] [Full Text] [Related]
9. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. Lonn EM; Bosch J; López-Jaramillo P; Zhu J; Liu L; Pais P; Diaz R; Xavier D; Sliwa K; Dans A; Avezum A; Piegas LS; Keltai K; Keltai M; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Parkhomenko A; Khunti K; Toff WD; Reid CM; Varigos J; Leiter LA; Molina DI; McKelvie R; Pogue J; Wilkinson J; Jung H; Dagenais G; Yusuf S; N Engl J Med; 2016 May; 374(21):2009-20. PubMed ID: 27041480 [TBL] [Abstract][Full Text] [Related]
10. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review. Lacourcière Y Clin Exp Hypertens; 2013; 35(1):50-60. PubMed ID: 22866964 [TBL] [Abstract][Full Text] [Related]
11. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. Yusuf S; Bosch J; Dagenais G; Zhu J; Xavier D; Liu L; Pais P; López-Jaramillo P; Leiter LA; Dans A; Avezum A; Piegas LS; Parkhomenko A; Keltai K; Keltai M; Sliwa K; Peters RJ; Held C; Chazova I; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Sanchez-Vallejo G; McKelvie R; Pogue J; Jung H; Gao P; Diaz R; Lonn E; N Engl J Med; 2016 May; 374(21):2021-31. PubMed ID: 27040132 [TBL] [Abstract][Full Text] [Related]
12. The evening versus morning polypill utilization study: the TEMPUS rationale and design. Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539 [TBL] [Abstract][Full Text] [Related]
14. [In high risk patients also treat high normal blood pressure values!]. Düsing R MMW Fortschr Med; 2006 Mar; 148(13):5. PubMed ID: 16642693 [No Abstract] [Full Text] [Related]
15. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010 [TBL] [Abstract][Full Text] [Related]
16. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920 [TBL] [Abstract][Full Text] [Related]
18. [Report of experiences. Walk in the woods by a retiree without leg edema]. Weisser B MMW Fortschr Med; 2001 Oct; 143(43):52. PubMed ID: 11715883 [No Abstract] [Full Text] [Related]
19. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks]. Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964 [No Abstract] [Full Text] [Related]
20. Cholesterol and inflammatory risk: Insights from secondary and primary prevention. Stock JK Atherosclerosis; 2019 Jan; 280():192-193. PubMed ID: 30458965 [No Abstract] [Full Text] [Related] [Next] [New Search]